Long‐term remission of small cell lung cancer after reactivation of tuberculosis following immune‐checkpoint blockade: A case report

Immune‐checkpoint inhibitors (ICIs) provide a promising treatment option for advanced tumors including small cell lung cancer (SCLC). Nevertheless, in addition to immune‐related adverse events (irAEs), an increased risk of infection including tuberculosis has been previously described. Here, we repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirgiovanni, Mattia, Hinterleitner, Clemens, Horger, Marius, Atique, Naushad Bijoy, Lauer, Ulrich M., Zender, Lars, Hinterleitner, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919119/
https://www.ncbi.nlm.nih.gov/pubmed/33458956
http://dx.doi.org/10.1111/1759-7714.13821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919119/
https://www.ncbi.nlm.nih.gov/pubmed/33458956
http://dx.doi.org/10.1111/1759-7714.13821

Ejemplares similares